Recent Advances in Medical Therapy for Urological Cancers
The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play important roles in these malignancies. However, i...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.746922/full |
| _version_ | 1818355996977790976 |
|---|---|
| author | Takeshi Yuasa Tetsuya Urasaki Ryosuke Oki |
| author_facet | Takeshi Yuasa Tetsuya Urasaki Ryosuke Oki |
| author_sort | Takeshi Yuasa |
| collection | DOAJ |
| description | The mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play important roles in these malignancies. However, immune checkpoint inhibitors (ICIs) that target PD-1/PD-L1 or CTLA-4 are being rapidly introduced for the treatment of metastatic urological cancers, just as they have been for other malignancies. Currently, the paradigm of medical treatment for patients with metastatic urological cancer is dramatically changing. Accordingly, we need to organize and summarize the new therapeutic tools, which include immune checkpoint inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs). This review provides an overview of agents and regimens that have just launched or will be launched in the near future in Japan. Based on the promising anti-tumor efficacy and manageable safety profiles being demonstrated in clinical trials, these new agents and therapies are expected to be rapidly introduced in Japanese clinical practice. Additionally, the newly designed ADC, enfortumab vedotin, which comprises a fully human monoclonal antibody conjugated to an anti-cancerous agent via a protease-cleavable linker, has just been launched in Japan. In order to provide the optimal treatment for our patients, we need to completely understand these new therapeutic tools. |
| first_indexed | 2024-12-13T19:50:12Z |
| format | Article |
| id | doaj.art-181c46d569c5411f8f5782c54f224e96 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-13T19:50:12Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-181c46d569c5411f8f5782c54f224e962022-12-21T23:33:26ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.746922746922Recent Advances in Medical Therapy for Urological CancersTakeshi Yuasa0Tetsuya Urasaki1Ryosuke Oki2Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanDepartment of Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, JapanThe mainstay of medical treatment has been tyrosine kinase inhibitors (TKIs) for renal cell cancer (RCC), cytotoxic chemotherapy for urothelial cancer (UC), and androgen deprivation therapy for prostate cancer. These therapeutic modalities still play important roles in these malignancies. However, immune checkpoint inhibitors (ICIs) that target PD-1/PD-L1 or CTLA-4 are being rapidly introduced for the treatment of metastatic urological cancers, just as they have been for other malignancies. Currently, the paradigm of medical treatment for patients with metastatic urological cancer is dramatically changing. Accordingly, we need to organize and summarize the new therapeutic tools, which include immune checkpoint inhibitors, poly (ADP-ribose) polymerase (PARP) inhibitors, and antibody-drug conjugates (ADCs). This review provides an overview of agents and regimens that have just launched or will be launched in the near future in Japan. Based on the promising anti-tumor efficacy and manageable safety profiles being demonstrated in clinical trials, these new agents and therapies are expected to be rapidly introduced in Japanese clinical practice. Additionally, the newly designed ADC, enfortumab vedotin, which comprises a fully human monoclonal antibody conjugated to an anti-cancerous agent via a protease-cleavable linker, has just been launched in Japan. In order to provide the optimal treatment for our patients, we need to completely understand these new therapeutic tools.https://www.frontiersin.org/articles/10.3389/fonc.2022.746922/fullimmune checkpoint inhibitorPARP inhibitorolaparibantibody-drug conjugateandrogen receptor axis targeted agentenfortumab vedotin |
| spellingShingle | Takeshi Yuasa Tetsuya Urasaki Ryosuke Oki Recent Advances in Medical Therapy for Urological Cancers Frontiers in Oncology immune checkpoint inhibitor PARP inhibitor olaparib antibody-drug conjugate androgen receptor axis targeted agent enfortumab vedotin |
| title | Recent Advances in Medical Therapy for Urological Cancers |
| title_full | Recent Advances in Medical Therapy for Urological Cancers |
| title_fullStr | Recent Advances in Medical Therapy for Urological Cancers |
| title_full_unstemmed | Recent Advances in Medical Therapy for Urological Cancers |
| title_short | Recent Advances in Medical Therapy for Urological Cancers |
| title_sort | recent advances in medical therapy for urological cancers |
| topic | immune checkpoint inhibitor PARP inhibitor olaparib antibody-drug conjugate androgen receptor axis targeted agent enfortumab vedotin |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.746922/full |
| work_keys_str_mv | AT takeshiyuasa recentadvancesinmedicaltherapyforurologicalcancers AT tetsuyaurasaki recentadvancesinmedicaltherapyforurologicalcancers AT ryosukeoki recentadvancesinmedicaltherapyforurologicalcancers |